BAX/BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 60, Issue 8, 2013, Pages

  Sharawat, Surender Kumar ^a   Bakhshi, Radhika ^b   Vishnubhatla, Sreenivas ^c   Gupta, Ritu ^a   Bakhshi, Sameer ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b UNIVERSITY OF DELHI   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Acute myeloid leukemia; BAX BCL2; Prognosis; Real time PCR; Taq Man probe

Indexed keywords

CYTARABINE; DAUNORUBICIN; PROTEIN BAX; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; GENETIC ASSOCIATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION;

ADOLESCENT; BCL-2-ASSOCIATED X PROTEIN; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84879199499     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24518     Document Type: Article

References (11)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
2. Testa U, Riccioni R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007; 92:81-94.
3. Schimmer AD, Hedley DW, Penn LZ, et al. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: A translational view. Blood 2001; 98:3541-3553.
4. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by BAX/BCL2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101:2125-2131.
5. Karakas T, Maurer U, Weidmann E, et al. High expression of BCL2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9:159-165.
6. Köhler T, Schill C, Deininger MW, et al. High Bad and BAX mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia 2002; 16:22-29.
7. Kornblau SM, Vu HT, Ruvolo P, et al. BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clin Cancer Res 2000; 6:1401-1409.
8. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322-2333.
9. Liu Yin JA, Wheatley K, Rees JK, et al. Comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113:713-726.
10. Chleq-Deschamps CM, LeBrun DP, Huie P, et al. Topographical dissociation of BCL2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993; 81:293-298.
11. Akagi T, Kondo E, Yoshino T. Expression of BCL2 protein and BCL2 mRNA in normal and neoplastic lymphoid tissues. Leuk Lymphoma 1994; 13:81-87.